{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:35:14Z","timestamp":1763534114745,"version":"3.37.3"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0229517","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T13:33:25Z","timestamp":1582810405000},"page":"e0229517","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-2977","authenticated-orcid":true,"given":"Apichet","family":"Sirinawasatien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaya","family":"Techasirioangkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"1","key":"pone.0229517.ref001","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"JM Pawlotsky","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0229517.ref002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 5","key":"pone.0229517.ref003","first-page":"S79","article-title":"Risk factors of hepatitis C virus infection in blood donors in Thailand: a multicenter case-control study","volume":"89","author":"T Tanwandee","year":"2006","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"pone.0229517.ref004","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"J Hepatol"},{"key":"pone.0229517.ref005","doi-asserted-by":"crossref","first-page":"e0126764","DOI":"10.1371\/journal.pone.0126764","article-title":"Genotypic Distribution of Hepatitis C Virus in Thailand and Southeast Asia","volume":"10","author":"R Wasitthankasem","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0229517.ref006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3851\/IMP1935","article-title":"egylated interferon-\u03b12a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003\u20132007)","volume":"17","author":"M Bourli\u00e8re","year":"2012","journal-title":"Antivir Ther"},{"key":"pone.0229517.ref007","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2036.2008.03763.x","article-title":"Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis","volume":"28","author":"A Andriulli","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0229517.ref008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1665-2681(19)31678-3","article-title":"Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-interferon\u2014Ribavirin in daily practice","volume":"9","author":"E Ridruejo","year":"2010","journal-title":"Ann Hepatol"},{"key":"pone.0229517.ref009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0229517.ref010","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"67","author":"AASLD\/IDSA HCV Guidance Panel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pone.0229517.ref011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/jcpt.12426","article-title":"Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis","volume":"41","author":"VL Ferreira","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"pone.0229517.ref012","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/jmv.23962","article-title":"Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy","volume":"86","author":"K Kumthip","year":"2014","journal-title":"J Med Virol"},{"key":"pone.0229517.ref013","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"M Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"pone.0229517.ref014","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"GR Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"pone.0229517.ref015","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0229517.ref016","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0229517.ref017","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"A Abergel","year":"2016","journal-title":"Hepatology"},{"key":"pone.0229517.ref018","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"MG Swain","year":"2010","journal-title":"Gastroenterology"},{"key":"pone.0229517.ref019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jgh.12865","article-title":"Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis","volume":"30","author":"W Kemp","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0229517.ref020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"M Ziol","year":"2005","journal-title":"Hepatology"},{"key":"pone.0229517.ref021","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.cgh.2007.07.020","article-title":"Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis","volume":"5","author":"JA Talwalkar","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0229517.ref022","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"M Friedrich-Rust","year":"2008","journal-title":"Gastroenterology"},{"key":"pone.0229517.ref023","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"L Castera","year":"2008","journal-title":"J Hepatol"},{"key":"pone.0229517.ref024","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/liv.12808","article-title":"Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study","volume":"35","author":"YS Seo","year":"2015","journal-title":"Liver Int"},{"key":"pone.0229517.ref025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"European Association for Study of the Liver, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0229517.ref026","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40261-017-0521-4","article-title":"Efficacy of interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials","volume":"37","author":"VL Ferreira","year":"2017","journal-title":"Clin Drug Investig"},{"key":"pone.0229517.ref027","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/jgh.13620","article-title":"Ledipasvir\/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: a pairwise meta-analysis","volume":"32","author":"VL Ferreira","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0229517.ref028","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0229517.ref029","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"pone.0229517.ref030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"JP Messina","year":"2015","journal-title":"Hepatology"},{"key":"pone.0229517.ref031","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","author":"EJ Gane","year":"2015","journal-title":"Gastroenterology"},{"key":"pone.0229517.ref032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jvh.12609","article-title":"Community-based real-world treatment outcomes of sofosbuvir\/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States","volume":"24","author":"RJ Wong","year":"2017","journal-title":"J Viral Hepat"},{"key":"pone.0229517.ref033","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/jvh.12721","article-title":"Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1\u20134 and 6 in Myanmar: Real-world experience","volume":"24","author":"NKT Hlaing","year":"2017","journal-title":"J Viral Hepat"},{"key":"pone.0229517.ref034","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir","volume":"60","author":"G Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0229517.ref035","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"JJ Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0229517.ref036","first-page":"87","article-title":"Efficacy of Treating Chronic Hepatitis C Genotype 3 Infection with Peginterferon Alfa plus Ribavirin in Real-world Practice","volume":"101","author":"A Sirinawasatien","year":"2018","journal-title":"J Med Assoc Thai"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T13:33:40Z","timestamp":1582810420000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229517"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0229517","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}